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ABSTRACT 
THE EFFECT OF PROTEOLYTIC QUEUES ON ANTIBIOTIC TOLERANCE AND 
PERSISTENCE CELLS POPULATION IN ESCHERICHIA COLI 
ALAWIAH ABUALRAHI 
2019 
A major contributing factor to the abundance of antibiotic-resistant microorganisms and 
failed antibiotic treatment is survival due to antibiotic tolerance and persistence. Antibiotic 
tolerance is a widespread phenomenon that enables cells to survive treatment without 
carrying a resistance gene. This phenomenon renders antibiotic treatments less effective 
and facilitates antibiotic resistance. We are particularly interested in proteases, responsible 
for degradation of proteins, because of their known relationship to tolerance and 
persistence. Here, we examine the effects of proteases and antibiotic survival using 
queueing theory, in which one type of customer competes for processing by servers, that 
has traditionally been applied to systems such as computer networks and call centers. The 
biological queueing theory principally assumes that there are limited processing resources 
in a cell. Using synthetic systems engineered to form proteolytic queues, we can now 
examine tolerance/persistence in a new manner. In this work, we demonstrated in E. coli 
that the overproducing of protein engineered to be digested by the protease ClpXP can form 
a proteolytic queue, and this queue results in an increase in antibiotic tolerance ~80 and 
~60 fold with ampicillin and ciprofloxacin, respectively. The proteolytic queue had no 
apparent effect on bacterial persistence levels. Furthermore, we showed that the queueing 
at the other two major proteases, ClpAP and Lon, have a slight effect on tolerant cell 
population.  
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Chapter 1 
Literature Reviews 
 
1.1. Introduction  
The discovery of antibiotics about 90 years ago that selectively target human and 
animal pathogens was a great advance in human health. However, antibiotic resistance is a 
growing problem for both human health1 and livestock production2. For example, 
Salmonella infections in the US alone lead to annual economic losses of about 1.3 billion 
dollars, and, in 2005, the poultry industry lost approximately one million birds, mainly due 
to bacterial infections2. The US Department of Agriculture (USDA) Economic Research 
Service (ERS) estimates that foodborne illnesses annually cost over $15 billion3. Bacterial 
infections lead to other economical loses in all industries, such as employees missing work 
due to infections, and product infection in the agricultural industry. In 2013, the Center for 
Disease Control (CDC) estimated that over 2 million Americans had antibiotic-resistant 
bacterial infection over the course of that year4. Due to the wide impact of antibiotic 
resistance, the phenomenon has become a growing concern worldwide, as antibiotic-
resistant organisms continue to arise and propagate5. In this work, we focus on bacterial 
tolerance and persistence to antibiotic treatment with the long-term goal to produce new 
drugs to prevent both of them. 
 
  Persister and tolerant cells are subpopulations commonly found in bacteria that 
precipitate antibiotic resistance; tolerant cells can survive the duration of a transient 
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antibiotic treatment several times above the minimum inhibitory concentration (MIC) 
without a resistance mechanism6.  MIC is the lowest concentration of the antibiotics, which 
inhibits visible growth of bacteria. The persistent state is a dormant (metabolically inactive) 
state that enables many bacterial species to maintain a subpopulation (about 1/10,000 to 
1/1,000,000) of cells in the harsh changes in the environment including antibiotic 
treatment7-9.   
 
  Bacterial persistence is considered a major contributing factor to chronic bacterial 
infections7, 10-12, and has been identified in nearly all major bacterial pathogens10, 13. A 
major reason why persister cells are so hard to study is that they are genetically 
indiscernible from the vegetative (non-persister) population and not evident with common 
clinical tests13, 14. Furthermore, repeated treatment with antibiotics without killing of the 
population can have traumatic effects such as increased persistence and resistance levels 
in a bacterial population15. Persister cells that survive antibiotic treatment can acquire 
antibiotic resistance genes from their neighbors11, 12, or mutate resulting in resistance. 
 
Though our knowledge of the mechanism of persistence is limited, even with over 70 
years of research, we do know of a few important components involved. One group of 
proteins related to tolerance/persistence I explored specifically during graduate school are 
proteases, proteins that degrade other proteins. In addition to proteases, toxin-antitoxin 
(TA) systems16-19 are protein networks that have been shown to play a role in the persister 
state, and I study them briefly in Chapter 4. Because our understanding of persister and 
3 
 
tolerant cell is poorly understood and it has been studied using traditional approaches, here 
we take a new approach.  
 
1.2. Overview 
1.2.1. Escherichia coli 
In this work, we used E. coli to study tolerance and persister cells. E. coli cells are 
normally rod-shaped, and they are gram-negative facultative bacteria (can grow in aerobic 
and anaerobic conditions). E. coli is of particular importance to human and animal health 
because they are commonly found in the human and agriculturally important animals such 
as cows, sheep, and goats. For human and animal health, most E. coli strains are non-
pathogenic; however, some can cause serious diseases such as diarrhea, urinary tract 
infections, respiratory illness and pneumonia, and other illnesses20, 21. For example, E. coli 
0157 h7 can cause deadly infections leading to kidney failure22. E. coli infections are often 
acquired by contaminated foods and water or by touching animals carrying E. coli without 
washing hands well. Unfortunately, E. coli infections from feces material23 is still prevalent 
around the world due to the lack of sanitary waste removal. In this study, we used a non-
pathogenic lab strain of E. coli as a model, and we kill susceptible cells by using antibiotics. 
 
1.2.2. Antibiotics 
In this study, we used specific antibiotics to isolate persister cells from non-persister 
cells. In the first half of the 19th century, the discovery and production of antibiotics has 
been argued as one of medicine’s greatest achievements24. Alexander Fleming discovered 
the first antibiotic, penicillin25-27, and in the 1950 to 1960, many new antibiotics were 
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discovered; about 50% of the antibiotics that we use today were discovered in this period26, 
28. Antibiotics have been used to control infectious diseases and lower human morbidity 
and mortality29. For instance, the average life span in the USA was only 56 years in the 
1920s before antibiotics were used, but now the average life span in the USA is nearly 80 
years due to in part antibiotic treatment30. During surgery, antibiotics are used as a means 
to prevent potential infections. Moreover, antibiotics are particularly important for 
immune-compromised individuals to prevent infections, e.g. for patients receiving 
chemotherapy treatments, chronic diseases such as diabetes, and many more30. 
 
1.2.3. Mechanisms of antibiotic action against bacterial cells 
Most antibiotics target the cellular processes of mRNA translation, RNA transcription, 
DNA replication, and cell wall synthesis (Fig. 1.1). Below, I briefly describe the 
mechanisms of the antibiotics used in this work: ampicillin (Amp), ciprofloxacin (Cip), 
and chloramphenicol were used in tolerance and persistence experiments, while 
chloramphenicol and kanamycin (Km) were used to maintain plasmids in E. coli.  
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Fig. 1.1 Targets of common antibiotics used to kill bacteria. 
1.2.3.1. A brief description of the antibiotics used in this work:   
 
1.2.3.1.1. Ampicillin (Amp) 
The major antibiotics we used to treat E. coli population in this work was Ampicillin 
(Amp). Amp, like all β-lactams, interferes with steps in homeostatic cell wall 
biosynthesis31. Treatment with a cell wall synthesis inhibitor like Amp first causes a change 
in cell form and size, induce cellular stress responses, and then cell lysis31, 32. Many gram-
positive and some gram-negative pathogenic bacteria can be treated with Amp33. The 
amino group in Amp permits it to permeate the external membrane of gram-negative 
bacteria, and there it acts as an inhibitor of transpeptidase, which is needed for bacterial 
cell wall formation, and leads to cell lysis finally34. 
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Amp is used throughout this work to quantify persister and tolerant cell levels, but we 
used other classes of antibiotics to be sure that we were not quantifying an Amp-specific 
bacterial response. 
 
1.2.3.1.2.  Kanamycin (Km) 
Kanamycin (Km) is effective in treating many bacterial infections such as tuberculosis35, 
36, and it works against most gram-negative bacteria37. The mechanism of action for Km is 
well understood: it leads to bacterial cell death by binding to the bacterial 30S ribosomal 
subunit, which causes a misreading of t-RNA, and then the bacteria are incapable of 
synthesizing new proteins needed for growth and cell maintenance31.  
Here we use a Km selective marker in E. coli to maintain plasmids containing Km 
resistance38-40. We introduced synthetic gene constructs using a few plasmids (Table 1.1.).  
 
1.2.3.1.3. Chloramphenicol (Cm) 
Chloramphenicol (Cm) is used to treat different infections such as bacterial meningitis, 
cholera, typhoid fever, and the plague41. A benefit of Cm is that it is active against both 
gram-positive and gram-negative bacteria31. It prevents cell growth by inhibiting protein 
translation; it binds the bacterial ribosomes, blocking translation, and thus inhibiting 
bacterial growth42. Specifically, Cm targets the 50S subunit of the bacterial ribosome and 
then inhibits the translation by interacting with the central loop of the 23S rRNA to blocks 
peptidyl transferase activity43, 44. Here we use Cm for tolerance/persistence assays and as a 
selective marker to maintain plasmids in E. coli (Table 1.2.3.). 
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 1.2.3.1.4. Ciprofloxacin (Cip) 
Ciprofloxacin (Cip) is a wide-spectrum antibiotic of the fluoroquinolone (contain a 
fluorine atom in their chemical structure) class, and it works against both gram-positive 
and gram-negative bacteria45. It functions on inhibition topoisomerase (DNA gyrase) 
enzymes such as type II topoisomerase and topoisomerase IV46. Cip inhibits the relaxation 
of supercoiled DNA and promotes the breakage of double-stranded DNA. As a result of 
that Cip will inhibit cell division46. Here we use Cip for tolerance/persistence assays (Table 
1.2,3). 
 
Table 1.1 Plasmids used in this work with their antibiotic section’s marker and important 
functional units. 
Plasmid Antibiotic sections 
marker 
Functional units 
p24KmNB8347 Km [Plac/ara promoter cfp T1] [T1] [colE1 
origin] [KmR, T0] 
p24KmNB8247 Km [Plac/ara promoter cfp-LAA T0] [T1] 
[colE1 origin] [KmR, T0] 
p24KmNB7847 Km [Plac/ara promoter cfp-TS linker-MarAn20 
T1] [T1] [colE1 origin] [KmR, T0] 
p24KmNB0747 Km [Plac/ara promoter RepA70-cfp T1]; [colE1 
origin] [KmR, T0] 
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p24KmAA83 Km [Plac/ara-1 (A27) promoter cfp T1], [Plac/ara-1 
(A27) promoter] [T1 cfp] [colE1 origin] 
[T0, KmR] 
p24KmAAR Km [Plac/ara promoter rpoS T1] [colE1 origin] 
[KmR, T0] 
p31CmNB0247 Cm [PLteto-1 promoter yfp T1]; [T1]; [p15A 
origin, t0] [CmR] 
p31CmNB9547 Cm [PLteto-1 promoter yfp-LAA T0] [T1] 
[p15A origin, t0] [CmR] 
 
Table 1.2 Strains used in this work, their antibiotic section markers, and important 
functional units.  
 
Strains Antibiotic sections 
marker 
Functional units 
DH5alphaZ1 Streptomycin laciq, PN25-tetR, SpR, deoR, supE44, Delta 
(lacZYA-argFV169), Phi80 lacZDeltaM15, 
hsdR17(rK- mK+), recA1, endA1, gyrA96, thi-
1, relA1. 
JM109  endA1, recA1, gyrA96, thi, hsdR17 (rk
–, 
mk
+), relA1, supE44, Δ (lac-proAB), 
[F´ traD36, proAB, laqIqZΔM15]. 
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1.2.4. Antibiotics resistance  
Antibiotics constituted a great development in saving millions of lives of humans and 
animals. However, typically, after two to three years of antibiotic being on the market, 
antibiotic-resistant pathogens evolve48. This is a growing problem for human and animal 
health (and economically), because very few new antibiotics are being introduced on the 
market49.  
In a bacterial population, there are two types of bacteria: non-susceptible and 
susceptible. Susceptible bacteria are killed by the antibiotic, while non-susceptible bacteria 
are not. Non-susceptible bacteria may not contain the target for the antibiotic; for example, 
Mycoplasma is not a target of β-lactams such as Amp and penicillin, because these 
antibiotics target cell wall formation and mycoplasma is a cell wall-free bacteria50. Some 
non-susceptible bacteria are able to avoid the antibiotic by switching to an alternative 
mechanism to the target of the antibiotic51. Other non-susceptible bacteria can degrade or 
alter the structure of an antibiotic making it less or not effective at all51, 52. Another simple 
method the bacteria can use to resist antibiotics is by pumping them outside of the cell 
using efflux pumps, resulting in the antibiotic not reaching its target53. There are multiple 
mechanisms that bacteria cells use to stop or minimize the efficient of antibiotics, and I am 
specifically interested in the mechanisms they use, which does not require acquisition of 
new genes or mutation of existing DNA. 
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1.2.3.1. Antibiotic resistance mechanisms 
Bacteria including E. coli become resistant to antibiotics in two ways: by a genetic 
mutation (chromosomal mutations) or acquiring DNA (e.g. horizontal gene transfer 
(HGT)) from the environment30, 51, 54. 
 
1.2.4.1.1. Genetic mutations can lead to resistance  
Bacteria can become antibiotic-resistant by genetic mutations. Mutations of DNA 
underlie the evolution of all life; through natural selection, new DNA sequencings are 
selected based on their environment and preexisting DNA. Because pathogenic bacteria 
often have short generation times (here we use doubling time as a metric of growth), 
mutations can appear quickly; mutations such as those related to antibiotic resistance55. 
Mutations that allow for resistance to many antibiotics are well-documented, such as those 
for rifampicin, fusidic acid, or streptomycin55. 
Bacteria can have multiple mechanisms to survive antibiotic treatment. Some cells will 
pump the antibiotic out, while others reduce the permeability of the membrane that 
surrounds the cell so that the antibiotic is less likely to enter the cell51. In both cases, the 
antibiotic is still active, and the cell is minimizing the effect of the antibiotic. However, the 
negative effect of the antibiotic on the cell can be dissipated by the inactivation of the 
antibiotic. Some cells produce enzymes that degrade the antibiotic, while others using 
enzymes to modify the antibiotic by adding various chemical groups so that it is no longer 
functional56,52,57 (Fig. 1.2).  
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Fig. 1.2 Antibiotic resistance strategies in bacteria.  
 
1.2.4.1.2. Acquisition of antibiotic resistance gene(s)   
Bacteria can become resistant to antibiotics by acquiring antibiotics resistance genes 
from their environment without mutations and not through vertical transfer (VT). VT is the 
passing of DNA to offspring, while horizontal gene transfer (HGT) is the movement of 
DNA from one organism or virus to another. Resistant genes are transferred by the 
acquisition of a plasmid, a transposon, a virus, or by transformation (naked DNA 
acquisition). Conjugation (often referred to as bacterial mating) of plasmid DNA is a 
common method in which antibiotic resistance genes are shared58,51. What adds to the 
growing problem of antibiotic-resistant pathogens is that acquisition (or through mutation) 
of a resistance gene can lead to resists to more than one of antibiotics23 or increase the 
tolerance to other antibiotics.  
 
Decreased uptake 
Efflux pumps 
Outside pumps Inactivating enzymes Target alterations 
DNA 
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1.2.4. Tolerance and persistence. 
 
1.2.4.1. Relationship between resistance and tolerant/persister cells 
Tolerance and persistence allow for a greater probability of antibiotic resistance 
developing in a population, and I have decided to focus on these topics in my Master’s 
program. It is crucial to study tolerance/persistence to fight the growing antibiotic-resistant 
problem (Fig. 1.3). One study that investigated the evolution of antibiotic resistance in 
bacterial populations undergoing common antibiotic treatments, concluded that antibiotic 
tolerance raises over time and precedes antibiotic resistance59. Another study measured the 
effect of frequent treatment of a population with antibiotics. They found that frequent 
treatments with antibiotics cause the development of populations with higher persistence 
and resistance levels13.  
 
  
Fig. 1.3 When antibiotics are removed before all persister cells are killed, persisters will 
repopulate the environment (e.g. human organs or site of infection). The persister 
population gives more time for the population to evolve antibiotic resistance through 
mutation or acquisition through DNA exchange from the environment13, 59.  
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1.2.4.2. Lifestyle of persister                                                                                                  
Persister cells participate in the growth of antibiotic resistance. Even though persister 
population is a small fraction of the whole population, they are the main reason why non-
resistant bacteria survive antibiotic treatment14. Persistence arises from non-inheritance 
while antibiotic resistance results from alterations in genetic material. Persisters exist 
because of phenotypic diversity that is naturally present in bacterial populations (Fig. 1.4). 
Not only do persisters survive antibiotic treatment, but their survival increases the 
possibility that antibiotic-resistance genes evolve or are acquired60. 
 Despite advances in persistence research over the last 70 years, only a few drugs target 
persisters (none of which are used regularly for human or animal diseases) We hypothesize 
that in order to develop new persister-drugs we need to take new approaches. 
 
1.2.5.2.1. Mechanisms of Persistence  
Knowing metabolic mechanisms for persistence will help us to understand and study 
persisters. Although persistence was discovered in 1944, the mechanisms by which cells 
enter/exit persistence and persister metabolism are poorly understood, and vigorously 
debated in the scientific community. Various studies have shown that protein synthesis is 
slowed in persisters because of slower rates of both transcription and translation compere 
to vegetative (non-persister) cells7. Other metabolic processes such as oxidative 
respiration61 and antibiotic efflux62 have been implicated as regulators of persistence, but 
this is disputed7, 61-64, and has not been resolved. To complicate matters more, up until very 
recently the terms persistence and tolerance defined differently by various groups6. As I 
describe below, we use a clear distinct definition for both. 
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Fig. 1.4 Persister cells are still alive under environmental stress.  
 
1.2.4.3. Bacterial tolerance 
Tolerant cells are a subpopulation that can survive the duration of a transient antibiotic 
treatment several times above the minimum inhibitory concentration (MIC) for a short-
term without changes in their DNA7. In other words, an antibiotic tolerant cell is able to 
survive during antibiotic treatment without carrying a resistance factor; they can regrow 
after removal of the antibiotic.  
Both tolerance and persistence increase survival in the presence of an antibiotic. So far, 
most studies focus on a qualitative understanding of the molecular mechanisms, and the 
persistence and tolerance terms are often interchangeable. However, persistence affects 
only a subpopulation of cells for a much longer time than tolerance6 (see Chapter 2, Fig. 
2.1). In this study, we study persister/tolerant populations of E. coli bacteria, which make 
up a small fraction of the population.  
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1.2.6. Methods to study and isolation persister and tolerant subpopulations 
 
1.2.6.1. Traditional persister assays 
The most used method to study persister/tolerant cells is the traditional agar plate assay6, 
7. In this method, a bacterial population is treated with an antibiotic to kill susceptible 
(vegetative cells, non-persisters) cells, and the antibiotic is removed before the entire 
population is killed. The persister/tolerant cells form colonies that can be counted on an 
agar plate; the total number of colonies before and after treatment are compared, and the 
%survival is then calculated (Fig. 1.5). In this work, we used the traditional persister assays 
to study persister/tolerance cells. 
  
 
Fig. 1.5 Method of persister isolation. 
 
1.2.6.2. Fluorescence Activated Cell Sorting (FACS) of “persisters” 
A popular alternative method to isolation “persister” is Fluorescence Activated Cell 
Sorting (FACS). Many studies analyzed the fluorescent protein mCherry induction in 
persister cells, and displayed no noticeable mCherry fluorescence until the cell came out 
from “persistence” (started growing), then allowing transcription/translation to ramp up65, 
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and the low protein biosynthesis levels of persisters has been a fundamental principle of 
using FACS to sort and separate persisters from the population66. Though FACS is a useful 
method to monitor different types of cells, it could be argued that levels of false positive 
and false negative persisters could offset the results (thus persisters are in quotes in this 
section). Using this method cells are classified as persister only by lowered fluorescence, 
which is a disadvantage because there are many conditions that cells may have low 
fluorescence proteins like died or dying cells67. Additionally, in this method, they don’t let 
the persister cells grow after removal of the antibiotic, which is essential to demonstrate 
that cells are definitely persisters66. 
 
1.2.6.3. Microfluidic devices and microscopy are used to measure persister/tolerant 
cells. 
The third method to study persister cells uses microfluidic devices. Microfluidic 
technology in combination with microscopy is an excellent method to measure persistence 
and tolerance to antibiotics. Antibiotics can be added to cell populations for a set time, then 
removed, and the tolerance and persister cells can be identified. Using the images taken 
during such experiments, the lifestyle of cells can be tracked. This includes tracking many 
phenotypes (e.g. cell size and shape) and different physical differences (e.g. cell location 
in a microenvironment, phase of growth (dividing or not dividing), etc.) The microfluidic 
devices allow researchers to mimicking cellular microenvironments like a host and 
provides quantitative results at the single-cell level. Microfluidic devices have been used 
in persister research, due to the feature of applying single-cell tracking to identify persister 
cells in the pretreatment population59, 62, 65, 68. 
17 
 
We did not use microfluidic devices in the course of my research, but future work related 
to my projects are currently being carried out. I did not use them because the fundamentals 
of queueing-tolerance was easily determined using the traditional agar plate assays. In 
addition, low persister levels can be a challenge to track in bacteria because 1,000s of cells 
need to be imaged at a time to identify persisters in a population at 1,000 magnification 
(e.g. 1/1,000,000 would require several million cells to be imaged over time). 
 
1.2.7. Bacteria life cycle  
Persister/tolerant cell formation is related to the bacteria life. A typical bacteria life cycle 
includes different phases: the first phase is lag where bacteria are maturing, they have an 
active metabolism, but not dividing; the cellular metabolism is adapting to the new habitat. 
When the bacteria population has adapted to their environment, they can enter the second 
phase called log or exponential where the bacteria grow and divide, and the doubling of 
the population is typically quicker in this phase than any other phase. In addition, the cell 
population is more homogenous in log phase than other phases of growth69. Bacteria will 
enter stationary phase when the environment is limited by such things as nutrient and space, 
or if there is a shift in the environment such as a change in temperature or pH. In late log 
or early stationary phase the population of cells is shifting from log to stationary phase 
resulting in a more heterogeneous population than log phase. The bacteria become less 
metabolically active, and the number of the dividing bacteria is nearly equal to the number 
of those dying. The stationary population is heterogeneous70, 71 and this heterogeneity is 
directly related to persister formation. After the bacteria stay under extreme stress in the 
stationary phase, there is a rapid death of cells (called death phase). The dying bacteria 
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release nutrients into the environment which enable other bacteria to regrowth and stay in 
the long-term stationary phase for a long time72 (Fig. 1.6). In this work, we study 
persister/tolerance cells in the stationary phase culture of E. coli because many pathogens 
are more pathogenic or become pathogenic in stationary phase due to the environmental 
conditions14, so the number of the persister/tolerance cells are higher in this phase than in 
log phase73. Empirically, it is much easier and more quantitative to study microbes in 
stationary phase due to the growth rate more stable in this phase than in the log phase.  
 
 
Fig. 1.6 Bacteria growth curve consist of lag phase, logarithmic phase, stationary phase, 
death phase, long-term stationary phase. In this work, we started with cultures in stationary 
phase to normalize the starting cultures and because this is typical in persistence work65. 
When treating cultures with antibiotics, we determined that 1/100 dilution in fresh rich 
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media allows the population to switch from stationary to log phase in a reasonable amount 
of time. This is important because most antibiotics are most effective when cells are 
dividing. Due to the slower rate of the growth and division in the stationary bacteria, 
treating the cultures with antibiotics like ampicillin will kill the cells that are dividing, 
which is a small fraction of the population.  
 
1.2.8. Protease and chaperone  
Persister cells are affected by protease activity17, 74. Proteases and their chaperons are 
vital elements in the cells. Chaperones are proteins that refold or unfold proteins for 
degradation75. They play an important role in the stabilization of unfolded proteins by 
preventing them from unspecific binding while they are in the process of folding76. 
Misfolded proteins are often unfolded by chaperones and sent to proteases for degradation. 
Other proteins are degraded by proteases included proteins that are no longer needed, such 
as sigma factors, or proteins only needed for a short time77. Proteases allow for the 
recycling of amino acids, which is especially important when nutrients are limited78 (Fig. 
1.7). There are more misfolded proteins to degrade in stationary phase than in log phase79; 
however, there is less transcription in the stationary phase than in the log phase79.  In this 
work we study the role of proteases, which have an important role in the population of 
tolerance and persister cells. 
 
 
 
 
20 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.7 Proteases as limited resources. 
 
1.2.8.1. Proteases are used to do this study 
The ClpP protease is responsible for at least 70% of protein degradation in E. coli 80. 
 
1.2.8.1.1. ClpXP 
ClpXP is a AAA+ protease, consists of two components, ClpX and ClpP. ClpX is a 
chaperone, a hexametric ring that recognizes and binds to the degradation tags of proteins 
and unfolded the tertiary structure of the peptide tags by using the energy from ATP 
hydrolysis. ClpX transfers unfolded proteins to ClpP tetradecamer chamber (proteases)81. 
 
1.2.8.1.2. ClpAP 
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The ClpAP protease ATP-dependent and mainly was found to degrade starvation 
proteins. ClpAP includes two heterologous proteins ClpA has two ATP binding sites and 
stimulates the ATPase activity, and ClpP has the proteolytic active site to degrade the 
proteins target for degradation80. 
 
1.2.8.1.3. Lon 
 Like Clp proteases, Lon is an ATP-dependent protease responsible for the removal of 
abnormal and mutant proteins by degrading them. They also target specific proteins such 
as short-lived regulatory proteins including some antitoxins82. Lon consists of a AAA+  
ring-shape that surrounds the degradation chamber83. The AAA+ ring of the Lon proteases 
recognize the abnormal proteins and then translocate the unfolded polypeptide chain into 
an internal degradation chamber84.  
 
1.2.9. Synthetic biology 
Though there are different definitions of synthetic biology, I classify it as a new and 
expanding area of biological research and technology that links science to engineering 
using a multiple discipline approach. For diverse applications, synthetic biologists engineer 
complex artificial biological systems to investigate natural biological situations or to 
produce a product for industrial or medical applications. Synthetic biologists engineer 
simple genetic circuits with reduced complexity and increased controllability compared to 
natural systems, and when combined with quantitative data, these circuits can be developed 
to mimic natural systems85. My definition synthetic biology is multi-discipline made up of 
different fields of study such as chemistry, biology, computer science, and engineering. 
This cross-disciplinary approach allows us to go from idea to creation quickly, and, in 
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general, a higher likelihood of success compared to one perspective. The primary goal of 
synthetic biology is to design and build biological systems that give a desired behavior. In 
other words, the goal of synthetic biology is to make biology easier to engineer by 
designing and building new biological functions and systems not found in nature86. There 
are several examples of a redesign of existing, native biological systems for useful purposes 
e.g. golden rice, biofuels, and bio-chemicals86, 87. 
Synthetic biology utilizes the basics underlying natural systems to build and design 
new biological networks, which improves our understanding of natural networks. As 
synthetic biology moves forward and the tools for redesigning biological networks 
improve, so does our capability to engineer organisms with highly complex behaviors. In 
this work, we used a synthetic biology approach to study persister/tolerance cells by 
producing fluorescent proteins tagged to the different tags to form a queue at the major 
proteases. 
 
1.2.10. Synthetic gene network 
The objective of synthetic biology is to re-engineer molecular elements of the cell to 
harness the power of biology. There are many important applications of synthetic biology 
in biotechnology and medicine88. The goal is to advance our understanding of gene 
networks and organisms so that we can one day have the engineering capacity for life as 
we have for electrical devices such as digital circuits89. 
For nearly 20 years, there have been important activities directed to develop synthetic 
gene networks that mimic the working of natural systems. The advancement of synthetic 
biology and the quick development of the tools used to redesign biological networks 
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continues to improve our qualification to engineer organisms with complicated behaviors 
found in natural systems. Diverse architectures have been explored, such as toggle 
switches, binary logical circuits, and negative and positive autoregulatory networks90-92. 
Recently, synthetic circuits have been developed that are regulated at the transactional and 
degradational level by proteases, while most synthetic networks are regulated at the 
transcriptional level93, 94.  
Through the previous years, there have been various successful efforts on improving a 
synthetic oscillatory network controlled at the gene regulation level95. These networks 
involved only two or three components, and mathematical modeling was instrumental in 
the process of designing and analyzing the network structure and developing the theory 
behind the network’s ability to drive periodic behavior. These successes in building 
networks capable of complex dynamic behavior validate the synthetic biology approach 
and demonstrate the power of computational modeling for understanding and predicting 
biological behavior. 
 
1.2.10.1. Basics of synthetic genetic circuits related to this work  
In this work, we used simple synthetic genetic circuits to probe persister/tolerant cell 
populations. We used plasmids that have a Plac/ara-1 promoter, which is a fusion of the lac 
promoter and arabinose (ara-1) promoter96. The LacI repressor inhibits expression by 
blocking the operator. The operator is responsible for the transcription of a gene to RNA, 
so when the operator blocked by LacI repressor, the proteins will not be produced. The 
chemical inducer isopropyl b-D-1-thiogalactopyranoside (IPTG) was used as an inducer 
by binding to the LacI protein, and thus removing it from the DNA and allowing for 
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transcription. In our experiments, IPTG induced the production fluorescent proteins cyan 
fluorescent protein (CFP). To further control this system and produce high level of the 
target protein, arabinose is added as an inducer. Arabinose binds to the transcription factor 
AraC, and together they induce expression of the cyan fluorescent protein (CFP) gene (Fig. 
1.8.A). One benefit of using this system is that LacI blocks the ability of the arabinose-
AraC complex to induce expression unless IPTG is added. This gives us excellent control 
and tunability of the system. 
We used another promoter, PLtet-1
96, which is repressed by the TetR protein, blocks the 
operator. Doxycycline (Dox) is a chemical inducer that binds the TetR repressor, thus 
releasing it from the DNA, and allows for expression of the target gene (YFP) (Fig. 1.8.B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
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Fig. 1.8. A. Basic model of the Plac/ara-1 promoter used to control CFP production, and the 
B. PLtet-1 promoter used to control YFP production.  
 
1.2.11. Queueing theory 
There are powerful theoretical connections between a large class of processing 
pathways in biological systems and queueing theory. Queueing theory, the study of waiting 
lines (in which one type of customer competes for processing by servers), has traditionally 
been applied to systems such as computer networks and call centers97, 98 (Fig. 1.9). 
B. 
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Queueing theory has newly been applied to biological systems based on computational 
models and synthetic biology principles. It was found that traditional queueing regimes 
neatly organized the qualitative statistical properties of a system in which one or more 
proteins compete for an enzyme99. In the so-called underloaded regime (where enzymatic 
processing is able to maintain with the arrival of new proteins), the coupling between 
different kinds of proteins was weak. However, different kinds of proteins highly induced 
one another by effectively competing for degradation in the overloaded regime (where 
enzymatic processing is incapable of maintaining with the inflow of new proteins). The 
transition between these regimes takes place at the balance point where there is a strong 
statistical phenomenon called correlation resonance, which is a massive correlation 
(approaching a correlation equal to one) reliably arising via critical protein competition. 
These results were expanded to a substantially wider class of models that included large 
processing networks100, and later it was explained that these results were not sensitive to 
diverse competing enzymes (e.g. proteases) in the cell98. 
In this work, we synthetically induce the expression of fluorescent proteins linked to 
various tags to study the effect of proteolytic queueing on persistence and tolerance 
population at different proteases. 
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Fig. 1.9 Queueing theory, the study of the waiting lines. The difference between the amount 
of time when there are multiple services and waiting line and when there are only one 
service and long waiting line. 
 
1.2.12. Toxin-antitoxin (TA) systems 
Persisters survive antibiotic treatment because of reduced metabolic activity compared 
to susceptible cells; particularly slower protein biosynthesis presumably caused by toxins 
in toxin-antitoxin (TA) systems; high concentrations of a toxin in the absence of its cognate 
antitoxin slows translation and increases persistence101. TA systems are genetic systems 
consisting of a toxin and an antitoxin. The toxin is a protein, while the antitoxin is either a 
small RNA or a proteins102. Natural networks of TA systems consist of several low copy 
number genes that may interact to gate and otherwise regulate persistence. 
TA systems have been introduced into eukaryotic cells (normally do not contain TA 
systems), and the toxin caused slowed growth well the antitoxin neutralized the toxin 
(normal growth)103. While TA systems have primarily been studied as a way to trigger 
persistence in bacteria, they have also been used to genetically engineer yeast, human cell 
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lines, and other eukaryotic cells for various studies, including antiviral applications103. In 
Chapter 4, we analyzed 16 type II TA systems at the transcriptional level. 
 
1.2.13. The role of proteases in persister 
Many studies have shown that proteases, such as Lon and ClpP, have an important role 
in persistence16, 17. Traditional methods of studying proteases and their effects depend on 
gene knockouts and overexpression; those methods can harmfully affect cell physiology 
and slow growth109-110. For example, clpP knockouts have growth defects
80, 104, while a 
drug that targets persisters (ADEP4), activates the protease ClpP and lowers persister 
levels105. 
Researchers who used traditional methods in studying persistence has shown that 
protease activity influences persister levels17, 74, 105, 106. One hypothesis in this area is the 
degradation of antitoxins by proteases (e.g. ClpXP) results in a cumulation of toxins 
stochastically so that a small number of cells switch into and the persistence state106. 
However, the latest results question this hypothesis and the role of TA systems in 
persistence remains controversial107, 108. This hypothesis is mostly relying on the fact that 
antitoxins are more labile than their cognate toxins16, 108. Because of that, free toxins are 
present when the amount of antitoxin is lower than the amount of toxin. When toxins are 
at a higher level than antitoxins the resulting free toxin activity triggers persistence109, 110. 
Proteases have a main role in this process because antitoxins are degraded faster than 
toxins, which leads to an excitable system111 (Fig. 1.10). However, the network structure 
of TA systems means that individual systems are integrated with the larger system; at the 
proteolytic level, TA proteins from multiple different TA systems are degraded by the same 
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protease16 (Table 1.3). Moreover, proteases supply an important level of protein regulation 
over the cell, and the role of proteolytic regulation in persistence worth further study. In 
this work, we study the effect of ClpXP, Lon, ClpAP proteases on the survival of cells, and 
quantify tolerant and persister cells. 
 
 
 
Fig. 1.10 Toxin-antitoxin (TA) systems. Antitoxins are degraded by proteases at a faster 
rate than toxin. So, when the number of toxins are higher than antitoxins the persister cell 
number increases. 
 
Table 1.3 Protein degradation tags47 targeted to proteases known to degrade TA system 
proteins (antitoxins) found in E. coli16. Note that degradation by different proteases may 
occur under different conditions (e.g. MazE is only known to be degraded by Lon during 
amino acid stress16, 112). Protease: Primary protease target. 
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Proteas Tag Tag description TA systems (A/T) 
Lon MarAn20 N terminus region of MarA 
YefM/YoeB, DinJ/YafQ, 
RelB/RelE, MazE/MazF, 
HigA/HigB, HipB/HipA, 
MqsA/MqsR, HicB/HicA 
ClpXP LAA 
Target for cellular ATP-dependent 
proteases 
DinJ/YafQ, MqsA/MqsR 
ClpAP RepA70 C terminus region of RepA MazE/MazF 
 
 
1.3. The objective of this study 
The purpose of this study, using a synthetic biology approach and queueing theory of 
proteases, was to examine the effect of overloading proteases (i.e. slowing protein 
degradation) on cell survival during antibiotic treatment. We focused on proteolytic 
queueing because it does not measurably affect growth rate47, 97, 98, 113, and does not disrupt 
protein networks dependent on these proteases. While the traditional method of knockouts 
and overexpression affects growth (thus persistence), and disrupts cellular networks, which 
could affect persistence.  
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Chapter 2 
Proteolytic queues at ClpXP increase antibiotic tolerance 
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2.1. Introduction  
The discovery of penicillin in the 1920s led to a new age of human and animal medicine 
as many antibiotics were quickly identified and developed, but the subsequent explosion 
of antibiotic treatments and applications has simultaneously driven microbial evolution and 
the development of widespread resistance48, 114. Cell survival of antibiotic treatment due to 
antibiotic tolerance and persistence11, 115 is a significant contributing factor to the 
abundance of antibiotic-resistant microorganisms. Persistence is a physiological state that 
enables cells to survive antibiotic treatment via temporary changes in phenotype, such as 
slowed growth and biosynthesis, rather than genotype (e.g. antibiotic resistance)116. 
Although persistence has been studied for over 70 years, there has been a lack of specificity 
in the literature between antibiotic tolerance and persistence63, 116. Recently, a consensus 
statement that was released after a discussion panel with 121 researchers defined antibiotic 
persistence as a tolerant subpopulation of cells that result in a distinct phase of population 
decay116. We use population decay to differentiate between tolerance and persistence in 
this work (Fig. 2.1).  
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Fig. 2.1 Examples of population decay in typical (black), high persistence (blue) and high 
tolerance (red) populations. A shift in tolerance can be distinguished from a change in the 
number of persisters. For example, a high persistence population can initially have the same 
decay rate as a typical population but have higher survival because of more persisters 
(dotted blue line). A high tolerance population can have the same persister level as a typical 
population but have a shift in the initial decay rate (dotted red line). b. A simple model of 
proteolytic queueing. When native proteins have low competition for the protease, there is 
no queue. Induction of synthetic tagged proteins competes with the native proteins for the 
protease and overloads the protease, which results in a proteolytic queue (bottleneck). 
The widespread nature of persistence suggests that similar mechanisms exist to trigger 
the persistent state in prokaryotes. These mechanisms include many common systems, e.g. 
toxin-antitoxin (TA) systems and proteases. Although the precise role of TA systems in 
persistence is unclear, toxins in TA systems can trigger persistence when at a higher level 
than their cognate antitoxin109, 110, 117. Within the cell, the ratio of toxin to antitoxin is 
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regulated during protein production118-120 and through degradation by proteases16, 121. 
Proteases, such as Lon and ClpP, are largely responsible for protein degradation and cell 
maintenance77, 122. They provide an essential level of protein regulation throughout the cell, 
including degradation of RpoS (a transcription factor that responds to stress)123 and tagged 
polypeptides (incomplete proteins) synthesized by stalled ribosomes that have been 
rescued by the trans-translation system124. In E. coli, ssrA (tmRNA) and smpB are the 
primary genes responsible for trans-translation, a cellular mechanism for recovering stalled 
ribosomes. A tmRNA molecule acts as a tRNA by binding to the A-site of a stalled 
ribosome. The ribosome is then transferred to translate the protein-coding region of the 
tmRNA, which adds an amino acid tag to target the polypeptide for degradation by 
ClpXP124. While ssrA is not essential in E. coli, ssrA knockouts cause growth defects, 
increase susceptibility to certain antibiotics125, and affect persistence18, 126. Proteases and 
related chaperones are also consistently identified as persister related genes in gene 
knockout experiments17, 127 and transcriptome analysis128. Indeed, a drug that targets 
persisters, acyldepsipeptide (ADEP4), activates the protease ClpP and lowers persister 
levels105. While most published articles focus on methods that reduce persister levels, 
conditions that increase their levels are integral to understanding the causative mechanisms 
of action and developing new drugs. As many persister studies incidentally examine 
antibiotic tolerance63, 116, it follows that some of the above mechanisms may play a role in 
antibiotic tolerance. 
Synthetic biology takes advantage of these mechanisms to develop new cellular circuits. 
For example, synthetic oscillators require rapid degradation of proteins, which is 
accomplished using the ssrA degradation tag97, 129, 130; the ssrA degradation tag is the amino 
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acid sequence, AANDENYALAA124, which we abbreviate to LAA throughout. Previous 
work establishes that multiple circuits can be coordinated by overproduction of a common 
degradation tag to target proteins to a protease98, 113. When a protease is overloaded, protein 
species compete for degradation; the enzyme is unable to keep up with the influx of new 
proteins99. This phenomenon can be explained by queueing theory, in which one type of 
customer competes for processing by servers, which has traditionally been applied to 
systems such as computer networks and call centers. Limited processing resources in a cell 
(e.g. proteases) cause biological queues47, 97 (Fig. 1b). The queueing effect at the protease 
ClpXP is essential in allowing for oscillation of the highly used synthetic oscillator (often 
called Stricker oscillator or dual-feedback oscillator)130, 131. Variations of this oscillator 
have been used in different strains of E. coli98, 113, 130, 132, and in  Salmonella typhimurium133, 
demonstrating that the queueing at ClpXP is not specific to one strain or species. The 
coupling of otherwise independent synthetic systems via proteolytic queueing 
demonstrates that queueing affects protein degradation and thus provides a tunable method 
of studying proteolytic degradation with little effect on cell growth47, 97, 98, 113 compared to 
gene knockouts and overexpression of proteases77, 80, 134.  
We set out to test the hypothesis that proteolytic queueing at the ClpXP complex effects 
survival of E. coli during antibiotic treatment. Previous studies have used knockout mutants 
to affect protease activity in E. coli, but these studies yielded mixed results17, 66, 126, 135. The 
variability between results of knockout mutations could be due to differences in growth 
rates, which would modulate antibiotic efficacy. Proteolytic queueing is preferred over 
protease knockouts when probing antibiotic efficacy because protease knockouts often 
result in growth defects77, 134, but proteolytic queueing does not noticeably affect cell 
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growth or death47, 97, 98, 113, even in stationary phase (Fig. 2.2). Our results show that during 
antibiotic treatment, degradation plays a role in cell survival and the effect is tunable using 
queue formation. Proteolytic queueing at ClpXP increases antibiotic survival and analysis 
of population decay with and without a queue demonstrates that queueing specifically 
increases antibiotic tolerance. We hypothesize that the queue is affecting the degradation 
of one or many regulatory molecules within the cell that cause downstream effects and 
enhance antibiotic tolerance. These results demonstrate that proteolytic queueing provides 
a new method to probe antibiotic tolerance and persistence. 
 
 
Fig. 2.2 Induction of untagged CFP and CFP-LAA tag has no apparent affect growth 
in MMB+ media. Colony-forming unit (CFU/ml) of induced and uninduced cultures over 
48 hours. n≥3. Error bars represent the standard deviation. Y-axis is in logarithmic scale.  
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2.2. Proteolytic queueing affects tolerance 
2.2.1. Proteolytic queueing affects tolerance 
At the beginning, we were working in the exponential phase, but we got confusing 
results due to the variables in the growth rate bacteria in this phase, so we moved to the 
stationary phase in order to get clear results. Cultures were grown to stationary phase and 
incubated for 24 hours prior to dilution into fresh media containing ampicillin to quantify 
persistence (see Methods). A proteolytic queue was induced via the production of a ssrA 
tagged fluorescent protein, CFP-LAA, expressed under an IPTG inducible promoter, 
Plac/ara-1. No apparent change in growth was observed by induction (Fig. 2.2) as reported 
previously98, 113. The effects of queue formation on antibiotic survival are shown as the 
percentage of the population that survived ampicillin treatment (Fig. 2.3). When CFP alone 
(the no degradation tag control) was overexpressed during ampicillin treatment, there was 
no significant effect on persister levels (p > 0.2, Fig. 2.3a). Queue formation 
(overexpression of CFP-LAA) during ampicillin treatment led to a 25-fold increase in 
survival after three hours in a concentration-dependent manner (Fig. 2.3b; p<0.0001, n ≥
12).  
When a queue was induced for 24 hours prior to ampicillin treatment the surviving 
population at three hours was over 80-fold higher than the uninduced population, only if 
induction was maintained during ampicillin treatment. However, if the inducer was 
removed during ampicillin treatment, the initial 24 hours of queueing had a minimal effect 
on survival at three hours (p>0.01, Fig. 2.3c). These results indicate that survival was 
affected by queue formation rather than CFP itself, and that the size of the queue (level and 
length of induction) determines the size of the effect. To confirm that these results are due 
37 
 
to induction during antibiotic treatment, we waited one hour into ampicillin treatment 
before inducing expression of the fluorescent protein. As we previously observed, 
induction of untagged CFP had no apparent effect on persister levels (Fig. 2.3d), while 
quantification of fluorescence after ampicillin treatment confirmed that CFP was produced 
(Fig. 2.3e). Overexpression of CFP-LAA for two hours of ampicillin treatment still 
increased cell survival compared to the uninduced and untagged CFP populations (Fig. 
2.3d). We did further testing to confirm this effect is not specific to glycerol as a carbon 
source or ampicillin as the antibiotic. When glucose was the carbon source rather than 
glycerol, survival still increased due to CFP-LAA induction (Fig. 2.3f), which 
demonstrates that the effect is not directly related to the carbon source. We then tested the 
effects of queueing against the antibiotic ciprofloxacin, because ciprofloxacin targets DNA 
gyrase136 while ampicillin targets the cell wall31. CFP alone caused a slight increase in 
survival (Fig. 2.4a), however the CFP-LAA tag leads to a 60-fold increase in survival (Fig. 
2.4b).  
 
2.2.2. Chloramphenicol inhibits the synthetic queue 
Neither ampicillin nor ciprofloxacin directly affect production of the fluorescent protein 
(i.e. target transcription or translation) and thus should not prevent queue formation. On 
the other hand, an antibiotic that affects protein production should prevent queue 
formation, and therefore CFP-LAA induction would not affect survival in the presence of 
such an antibiotic. We found this to be the case when testing the effects of queueing on the 
survival of cells treated with chloramphenicol. Chloramphenicol is an antibiotic that 
inhibits protein translation by binding to bacterial ribosomes and inhibiting protein 
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synthesis, thereby inhibiting bacterial growth42. Induction of CFP-LAA does not increase 
survival of antibiotic treatment. when treated with chloramphenicol alone (Fig. 2.5), but 
chloramphenicol is not bactericidal, so we co-treated cultures with both ampicillin and 
chloramphenicol. The overall percent survival with chloramphenicol is much higher than 
with ampicillin alone, which is consistent with the literature137. As expected, co-treatment 
with ampicillin and chloramphenicol had no apparent effect on cell survival, supporting 
that even when CFP-LAA was induced the queue could not form if translation was blocked 
(Fig. 2.3c).  
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Fig. 2.3 Proteolytic queueing affects survival of cells treated with the antibiotic 
ampicillin. a. Induction of untagged CFP during antibiotic treatment has no significant 
effect on survival (p>0.2). b. Induction of CFP-LAA during antibiotic treatment causes an 
increase in persistence. c. CFP-LAA was induced (+) with 100 µM of IPTG or not induced 
(-). Induction before ampicillin lasted 24 h in stationary phase prior to antibiotic treatment. 
Queueing only affects survival if the queue is maintained during ampicillin treatment. d-e. 
Expression of CFP or CFP-LAA was induced with IPTG one hour into the three-hour 
antibiotic treatment. Induction of CFP alone (no queue) had no significant effects on 
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survival. Induction of CFP-LAA increased survival (d). Population fluorescence was 
measured for untagged CFP after antibiotic treatment, demonstrating that CFP is being 
produced via induction (e). f. Induction of CFP-LAA during antibiotic treatment causes an 
increase in persistence with glucose as a carbon source rather than glycerol, demonstrating 
that it is not a solely a specific carbon source. 
 
 
 
 
Fig. 2.4 Proteolytic queueing effects in the presence of ciprofloxacin and 
chloramphenicol. a. Induction of untagged CFP during ciprofloxacin treatment increases 
survival less than 4-fold. b. Induction of CFP-LAA during ciprofloxacin treatment 
increases survival over 50-fold. c. Induction of CFP-LAA during ampicillin and 
chloramphenicol treatment has no apparent effect on persistence (p>0.7). X-axis labels 
correspond to Fig. 2. Error bars represent SEM. n≥3. *p<0.05. **p<0.01.  
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Fig. 2.5 Induction of CFP-LAA does not increase survival of chloramphenicol. 
Cultures were treated with chloramphenicol, an antibiotic that inhibits translation, after a 
1/10 dilution into fresh media from stationary phase. Induction of CFP-LAA via IPTG had 
no significant change in persistence compared to the uninduced cultures (p>0.7; n ≥ 3). 
Note that the % survival with chloramphenicol is much higher than ampicillin (alone), 
which is consistent with the literature137. Error bars represent SEM.  
 
2.2.3. Proteolytic queueing affects population decay 
To gain further insight into the relationship between proteolytic queueing, tolerance and 
persistence, we measured how a proteolytic queue affects population decay by measuring 
survival for up to 8 hours of ampicillin treatment. Our results show a typical biphasic curve 
indicative of persister cells in the uninduced population. When the population is induced 
24 hours prior to and during antibiotic treatment this curve shifts as the rate of population 
decay slows compared to uninduced cultures. The addition of the inducer exclusively 
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during antibiotic treatment takes a similar effect between two and three hours into 
treatment. If the queue is induced 24 hours prior to antibiotic treatment, but the queue is 
not maintained (i.e. the inducer is removed during antibiotic treatment) the effect of the 
queue dissipates between one to two hours. There is no apparent difference between 
induced and uninduced cultures after 8 hours, which suggests there is little to no effect on 
persistence (Fig. 2.6a). 
 
2.2.4. Computational modeling supports queueing-tolerance  
Based on the in vivo results, we considered a computational model of population decay 
during antibiotic treatment modified from Kussel et al.138. In our model, the persister 
population (P) has a lower death rate than the susceptible population (N), where the death 
rates are represented by µp and µn respectively. We estimated µp and µn based on the 
experimentally determined decay rate of the uninduced population before and after two 
hours and set the initial persister population to 0.2% of the total population (Fig. 2.6b). 
Normal (susceptible) cells enter persistence at rate α, and persister cells return to the normal 
state at rate β. The rates α and β were set relative to µn based on the relationship between 
these values in Kussel et al138. Our base model closely resembles population decay as 
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measured in experimental tests. We use the model to determine whether the increase in 
overall population survival due to queue formation can be attributed to an increased rate of 
entering persistence (α) or increased 
tolerance (i.e. decreased µn). 
Exploration of these parameters using 
stochastic simulations shows that 
increasing the rate at which normal 
cells become persisters (α) shortens 
the first phase of population decay and 
increases the number of persisters 
(Fig. 2.6c). Decreasing the rate of 
normal cell death (µn) lengthens the 
first phase of population decay but has 
little to no effect on the number of 
persisters (Fig. 4d) 
 
Fig. 2.6 Time of queue formation 
influences survival. a. Stationary 
phase cells were diluted 1/100 into 
fresh media containing ampicillin (100 
µg/ml) and sampled every hour for 8 h 
(n ≥ 3). Symbols (-/+) correspond to 
Fig. 2c. Error bars represent SEM. 
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Asterisks indicate p-value (compared to no induction (black)) *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. There is 100% survival at time zero, because percent survival 
is determined based on the surviving CFU/ml compared to the CFU/ml at time zero. b-d. 
Stochastic model of population decay with antibiotic treatment. b. Reactions for the model 
(left) and baseline rates used for the simulations (right) unless stated otherwise (red lines 
below). Normal cell division (ω) was set to zero as dividing cells die during ampicillin 
treatment. c. Increasing the rate of entering persistence (α) increases cell number during 
the second phase of population decay. d. Decreasing the rate of normal cell death (µn) 
causes the first phase of population decay to lengthen. 
 
2.3. Discussion  
Proteolytic queueing is an integral component of native systems that has great potential 
for applications outside of synthetic biology. Here we show that queueing provides a 
tunable method to interfere with protease degradation and affect antibiotic tolerance. 
Increasing antibiotic tolerance in response to queueing was independent of the carbon 
source (glycerol or glucose) and antibiotic class (β-lactam or fluoroquinolone). When we 
prevented queue formation using chloramphenicol, adding IPTG did not affect survival of 
ampicillin. While CFP production alone slightly increased survival for ciprofloxacin, we 
suspect that high production of CFP with no apparent method of removal (besides cell 
division; minimal degradation) causes cell stress and affects survival, especially since high 
levels of fluorescent proteins can cause oxidative stress139, 140, which is known to increase 
persistence141-143. However, because CFP-LAA is removed via degradation (indicated by 
lower fluorescence than CFP-untagged), the effects seen via overexpression of CFP should 
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be less prominent during CFP-LAA overexpression. The results we describe here would 
not have been identified in a clpP knockout, because clpP knockouts have growth defects80 
and any increase in tolerance would have been difficult to differentiate from this effect.  
In some cases, the change in survival at three hours might be interpreted as a change in 
persistence; however, the shift in decay rates (as described in Fig. 1a) clearly demonstrates 
that queueing increases antibiotic tolerance rather than persistence. Furthermore, the 
effects caused by adding or removing the inducer during antibiotic treatment suggest that 
the change in antibiotic tolerance is due to an active response to the queue, which must be 
maintained to affect survival. Although persistence does not appear to be affected by the 
proteolytic queue at ClpXP, further overloading ClpXP is possible. Alternatively, the 
synthetic queue may not form in persister cells due to slowed translation and transcription. 
Our model supports that antibiotic tolerance is being affected rather than persistence, as 
altering survival of the ‘normal’ population more closely resembles the effects of 
proteolytic queueing than altering the rate of switching into persistence.  
Queueing at ClpXP is likely affecting the proteome of the cell, either directly or 
indirectly, and pleiotropic effects on protein content and gene regulation could be limiting 
antibiotic efficacy. We suspect that queue formation increases the intracellular 
concentration of one or multiple protein species causing a regulatory cascade. When 
considering proteins both degraded by ClpXP and related to persistence, TA systems are 
unlikely to be the causative factor, because decreasing degradation should increase 
antitoxin levels and decrease survival rather than increase survival as we observe. 
Regulatory proteins are possible candidates for the causative factor in queueing effects on 
tolerance. Increased concentrations of these regulatory proteins due to slowed degradation 
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could be causing downstream effects that lead to increased tolerance. In a similar vein, 
computational modeling has shown that altering degradation of MarA (a regulatory protein 
related to antibiotic tolerance) leads to increased coordination of downstream genes144. 
Such proteins include RpoS and DksA (both degraded by ClpXP), which have been 
implicated in persistence126, 143, 145 and may be involved in tolerance. These and other 
regulatory proteins could be the cause of queueing-tolerance, as well as a yet unidentified 
protein(s). 
We have tested the effect of RpoS protein under the same conditions as proteolytic 
queueing to see if we could replicate the phenotype by overexpression of RpoS. Our results 
show that RpoS protein is not responsible for an increase in the number of tolerant cells 
(Fig. 2.7). 
The increase in antibiotic tolerance due to queue formation at ClpXP may be specific to 
overexpression of the LAA-tag, especially when considering that the number of LAA 
tagged proteins naturally increases during stress. The number of proteins with LAA tags 
increase during heat shock146, and queue formation at the proteases is likely a consequence 
of the increasing cellular traffic. If the native LAA tag is removed from SsrA while 
maintaining the ribosome rescue function, the survival of ampicillin treatment decreases in 
E. coli126. As the LAA tag could be a measurement of environmental stress, cells may have 
evolved to increase tolerance in response to increased queueing via LAA. Since ribosome 
rescue and proteolytic queueing are common across species, stress signaling via proteolytic 
queueing could be a general mechanism to regulate survival related genes. Identifying the 
key regulatory proteins in bacterial tolerance then understanding how these proteins 
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interact are of great interest because they provide potential targets for killing bacterial 
pathogens, and proteolytic queues are a new method to explore these regulatory elements.  
 
A. 
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C. 
 
 
 
Fig. 2.7. A.  p24kmAAR plasmid has RpoS gene under Plac/ara-1 promoter. B.  Induction of 
RpoS proteins during ampicillin treatment with glycerol as a carbon source (p<0.05). C. 
Induction of RpoS proteins during ampicillin treatment with glucose as sole a carbon 
source. Error bars represent SEM. n ≥ 3. 
 
2.4. Materials and Methods 
2.4.1. Strains and Plasmids 
All strains are derived from E. coli DH5αZ1, and contain plasmids with the synthetic 
circuits, p24KmNB82 (CFP-LAA) and p24KmNB83 (untagged CFP) as described in 
REF47 (Fig. 2.8). DH5αZ1 was derived from E. coli K12 (arguably the most studied 
bacteria strain147), it is used by many in synthetic biology and outside the field148-152, this 
strain has previously been used to study persistence/tolerance or mechanisms related to 
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them (e.g. toxin-antitoxin systems)65, 153, 154, and our previous queueing experiments used 
these derivitives47.  
The cultures were grown in modified MMA media155, which we will refer to as MMB. 
MMB media consists of the following: K2HPO4 (10.5 mg/ml), KH2PO4 (4.5 mg/ml), 
(NH4)2SO4 (2.0 mg/ml), C6H5Na3O7 (0.5 mg/ml) and NaCl (1.0 mg/ml). Additionally, 
MMB+ consists of MMB and the following: 2 mM MgSO4 x 7H2O, 100 µM CaCl2, 
thiamine (10 µg/ml), 0.5% glycerol and amino acids (40 µg/ml). Cultures grown on glucose 
as the carbon source included 0.5% glucose instead of glycerol. Strains containing the 
plasmid p24Km and derivatives were grown in MMB+ kanamycin (Km, 25 µg/ml) or on 
Miller’s Lysogeny broth (LB) agar plates + Km (25 µg/ml). All cultures were incubated at 
37ºC and broth cultures were shaken at 250 rpm. 
 
 
 
 
 
 
 
 
 
 
 
 
A. 
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Fig. 2.8. A. cfp-tagged to LAA under Plac/ara-1 promoter in the synthetic genetic circuit. B. 
cfp alone cloned in the plasmid p24KmNB83 components47. 
 
2.4.2. Quantification of persistence 
Persisters were quantified by comparing colony-forming units per milliliter (CFU/ml) 
before antibiotic treatment to CFU/ml after antibiotic treatment. The procedure for 
quantifying persister levels is based on previous research12, 65, 156 (Fig. 2.9). Briefly, 
overnight cultures were diluted 1/100 into fresh media and grown until they reach between 
OD600 0.2-0.3. A reduced volume of culture (20 ml) was aliquoted into a 125 ml flask and 
grown for 16 hours to enter stationary phase. Once in stationary phase, cultures were 
divided into two flasks with 0.2% arabinose, one flask of each replicate was also treated 
with 100 nM IPTG to induce expression under Plac/ara-1. Arabinose was added to both 
induced and uninduced cultures to maintain consistency (Fig. 2.10). All flasks were 
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incubated for 24 hours before taking samples for plating and antibiotic treatment; cells 
were diluted 1/10065, 156 into glass tubes, treated with 10X the MIC of ampicillin (100 
µg/ml) (Fig. 2.11) or 100X MIC of ciprofloxacin (1 µg/ml) at 37°C and shaken at 250 rpm 
for select time periods, 3 hours unless otherwise stated. Ampicillin solutions were stored 
at -80°C and only thawed once to reduce variability125, 157. When indicated, samples were 
treated with chloramphenicol (5 µg/ml); cultures treated with chloramphenicol alone were 
diluted 1/10. Samples for quantification of CFU/ml were kept on ice and diluted using cold 
MMB before plating on LB/Km (25 µg/ml) agar plates. Cultures treated with ciprofloxacin 
were centrifuged at 16,000 x g for 3 minutes then washed with cold MMB to dilute 
ciprofloxacin before taking samples for quantification. LB agar plates were incubated at 
37ºC for 40-48 hours, then scanned using a flatbed scanner59, 158. Custom scripts were used 
to identify and count bacterial colonies159 then calculate CFU/ml and persister frequency. 
Colonies were tested periodically for resistance, and we found no resistance in >350 
colonies tested (Fig. 2.12). 
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Fig. 2.9. A. Persister essay flow chart. See Methods for details. B. Pictures from the lab 
while I was doing persister assay and scanning the plates to use Fiji ImageJ program to 
count the colonies. 
 
B. 
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Fig. 2.10 The addition of arabinose had no apparent effect on the tolerance/persister 
level during ampicillin treatment. Both IPTG and arabinose are inducers for CFP 
untagged and CFP-LAA tagged proteins. IPTG induces expression, arabinose alone does 
not induce expression, but arabinose can enhance expression when used in combination 
with IPTG. The effect of adding arabinose (0.2%) on tolerance/persistence to ampicillin 
was tested with CFP-LAA. Adding arabinose does not have a significant effect on survival 
of cells after 3 hours of ampicillin treatment (p>0.3). Error bars represent SEM. n ≥ 3. 
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Fig. 2.11 Determination of Minimal Inhibitory Concentration (MIC) for ampicillin. 
Exponential phase cultures were treated with different concentrations of ampicillin. The 
MIC was determined to be 10 µg/ml (p <0.03 compared to zero). Error bars represent the 
standard deviation. 
 
 
 
Fig. 2.12 Testing the ampicillin resistance.  
Testing colonies for resistance, we found no resistance in 380 colonies tested. 
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2.4.3. Quantification of CFP  
 Cells were grown and treated with ampicillin as described in quantification of 
persistence above. After antibiotic treatment, 300 µl of cell culture was added to individual 
wells in a 96-Well Optical-Bottom Plate with Polymer Base (ThermoFisher) for 
fluorescence measurement using FLUOstar Omega microplate reader. The excitation and 
emission (Ex/Em) used for CFP measurement was 440/480. Readings were measured after 
four minutes of shaking to decrease variability between wells. Background fluorescence 
(mean fluorescence of MMB media) was subtracted from the raw reads. Fluorescence 
values were normalized by CFUs as determined by quantification of persistence, which 
was carried out simultaneously. Mean and SEM for fluorescence was determined across 
four biological replicates and three technical replicates.  
 
2.4.4. Computational modeling 
Our model is modified from Kussel et al.138 where P is the persister population and N 
is the susceptible population (Fig. 4b). Initial species counts P and N were set to 99800 and 
200 respectively for all simulations, which we based on the percent survival of uninduced 
cultures. The death rate of N (µn) and P (µp) and the rate of entering (α) and exiting (β) 
persistence were set as shown in Fig. 4b unless otherwise stated. The rate of susceptible 
cell division (ω) was set to zero, as normal cells cannot divide without lysis during 
ampicillin treatment68. All simulations were performed using a custom implementation of 
the Gillespie algorithm160 in Python leveraging optimizations made possible by the Cython 
library161. Libraries from the SciPy stack162 were used for analysis. 
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2.4.5. Statistics 
All data is presented as mean ± SD or SEM of at least 3 biological replicates as 
appropriate163. Statistical significance for populations with the same number of replicates 
(n) was determined using one-way f-test to determine variance (p<0.001 was considered to 
have significant variance) followed by a Student’s t-test (no variance) or a Welch’s t-test 
(significant variance). Populations with different n values were compared using a Welch’s 
t-test. All statistical tests were run in Python using libraries from SciPy on groups with at 
least three biological replicates.  
 
2.4.6. Data availability 
The data that supports the findings of this study are available from the corresponding author 
upon reasonable request. 
 
2.4.7. Code availability 
Code used for model simulations is available on GitHub at 
https://github.com/ctogle/mini_gillespiem. Code used for colony counting is available on 
GitHub at https://github.com/hdeter/CountColonies.  
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2.5. Data not included in the manuscript  
 
  
Fig. 2.13 Death curve for E. coli treated with ciprofloxacin. Y-axis: colony forming 
units (CFU/ml). X-axis: time from 0 to 4 hours. Error bars represent the standard 
deviation. N=3. 
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Fig. 2.14 Number of the survival cells under treatment with ciprofloxacin for 4 hours. 
Error bars represent the standard deviation. N=3. 
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Chapter 3 
The effect of proteolytic queuing at Lon and ClpAP proteases and using highly 
expressed tagged proteins on the tolerance/persistence 
3.1. Introduction  
    Persistence is a rare phenotypic switch that allows bacteria to be resilient against several 
factors, including antibiotics138. Antibiotic tolerance is a widespread phenomenon that 
enables cells to survive treatment without carrying a resistance gene164. This phenomenon 
makes antibiotic treatments less effective and increases antibiotic resistance 164. Persistence 
is affected by multiple systems, such as toxin-antitoxin165 (TA) and proteases activity16. 
    Proteolytic degradation is a crucial cellular process for recycling proteins and 
coordinating cellular activity. The traditional method of studying persistence and tolerance 
was to construct gene knockout or overexpression strains; however, these methods can 
result in harmful effects on the cell physiology and slow growth77, 134. Proteolytic queueing 
provides a new tool to affect proteolytic activity and probe natural systems without 
significantly growth rate47, 97, 98, 113.  
In the previous chapter, we explored the role of proteases in antibiotic tolerance, short-
term population survival of antibiotics, using queueing theory (i.e. the study of waiting 
lines) by using a synthetic system. The queue was formed by overproducing CFP-LAA 
which overloaded ClpXP proteases. The results demonstrated that overloading the ClpXP 
protease by CFP-LAA during treatment with ampicillin and ciprofloxacin results in an 
increase in antibiotic tolerance 80- to 60-fold, respectively, in an E. coli population. This 
tolerance-queueing effect was observed with two different types of antibiotics and carbon 
sources, and different times of induction of the queue.  
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In this chapter, the effect of queueing on tolerance or persistence at the other two major 
proteases, ClpAP and Lon, is tested. We synthetically caused a proteolytic queue by 
inducing expression of fluorescent proteins linked to RepA70 (tag RepA70, derived from 
a linker and a truncated version of the protein RepA166) and MarAn20 (MarA is degraded 
by Lon167 and 20 amino acids from the N-terminal of MarA47 was used to engineer the 
MarAn20 tag) at the medium level to examine the effect of proteases activity on the 
tolerance and persister population.  
Previous work established that strong proteolytic queueing was formed when the 
expression of LAA was at medium and high-levels47 (Fig. 3.1). However, previous work 
showed that a strong proteolytic queue formed when using RepA70 and MarAn20 tagged 
proteins only when these proteins were produced at high levels (not medium levels like 
LAA tagged proteins)47. I first tested the effect of proteolytic queueing on persistence and 
tolerance by overproducing LAA, RepA70, and MarAn20 tagged proteins a medium levels 
(Table 3.1).  
 
  
Fig. 3.1 Schematic diagram of proteolytic queuing at ClpXP induced by LAA tagged 
fluorescent proteins (YFP-LAA and CFP-LAA). During low production of LAA tagged 
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proteins, no queue forms (underloaded). During higher production of LAA tagged protein, 
queues forms (overloaded)47. 
Table 3.1 Degradation tags and protease primarily responsible for their degradation47. 
Tags Major Proteases Minor Proteases 
LAA ClpXP ClpAP, Lon 
MraAn20 Lon No 
RepA70 ClpAP ClpXP 
 
3.2. Materials and Methods. 
3.2.1. Strains and Plasmids 
All strains are derived from E. coli DH5αZ1, and contain plasmids with the synthetic 
circuits, p24KmNB78 (CFP-marAn20), p24KmNB07 (CFP-RepA70), p24KmNB83 
(untagged CFP), p24KmNB82 (CFP-LAA), p31CmNB02 (untagged YFP), and 
p31CmNB95 (YFP-LAA) as defined in REF47. The cultures were grown in modified MMA 
media155, which we referred to as MMB (see Chapter 2 Methods). Strains including the 
plasmid p24Km and derivatives were grown in MMB+ kanamycin (Km, 25 µg/ml) or on 
Miller’s Lysogeny broth (LB) agar plates + Km (25 µg/ml). Strains including the plasmid 
p31Cm and derivatives were grown in MMB+ chloramphenicol (10 µg/ml) on Miller’s 
Lysogeny broth (LB) agar plates + chloramphenicol (10 µg/ml). Broth cultures were shaken 
at 250 rpm. Cultures were incubated at 37ºC. 
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3.2.2. Quantification of persistence 
See methods as described in Chapter 2 to quantify the persister and tolerant cells. 
 
3.3. Results  
3.3.1. The effect of proteolytic queueing at Lon and ClpAP proteases on tolerance and 
persister population. 
We used E.coli strains derived from DH5αZ147 that contain p24KmNB78 (CFP-
marAn20), p24KmNB07 (CFP-RepA70) (Fig. 3.2). Stationary phase cultures were 
incubated for 24 hours and then diluted into fresh media containing ampicillin to quantify 
persister cells (see Methods Chapter 2). A proteolytic queue was produced through the 
production of the CFP tagged with MarAn20 and CFP tagged with RepA70, which were 
expressed under an IPTG inducible promoter, Plac/ara-1. Our results indicate that the 
induction of proteolytic queuing by CFP-MarAn20 or CFP-RepA70 during three hours of 
ampicillin treatment had a little effect on the tolerant population (Fig. 3.3.4). 
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Fig. 3.2. A. The p24kmNB78 plasmid contains cfp linked to a marAn20 tag under an IPTG 
inducible promoter Plac/ara-1. B.  The p24kmNB07 plasmid contains cfp linked to a repA70 
tag under Plac/ara-1 promoter. 
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B. CFP-MarAn20 
 
 
 
 
 
 
 
 
 
 Fig. 3.3. A. Induction of CFP-untagged has no apparent effect on the survival of cells 
during three hours of ampicillin treatment, p>0.23. B. The induction of CFP-MarAn20 
during antibiotic treatment has a minor, but significant, effect on resulting in an increase 
in the tolerant population. p<0.05. Error bars represent SEM. n ≥ 3. 
 
CFP-RepA70 
 
 
 
 
 
 
 
 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
IPTG- IPTG+
%
 S
u
rv
iv
a
l
0.0
0.5
1.0
1.5
2.0
2.5
3.0
IPTG- IPTG+
%
S
u
rv
iv
a
l
66 
 
Fig. 3.4 Inducing CFP-RepA70 under IPTG promoter during ampicillin treatment has a 
slight, but significant, effect on the tolerance population. Error bars represent SEM. p<0.05. 
n ≥ 3. 
 
3.3.2. The PLteto-1 promoter did not function as expected during stationary phase and 
is not ideal for work with tolerant and persister population  
We used a set of synthetic circuits in the E. coli DH5αZ147 (a common strain used in 
synthetic biology and outside the field148-152); the same strain used in Chapter 2. Using the 
same protocol as optimized in Chapter 2, we tested the effects of proteolytic queueing at 
different proteases on tolerance to antibiotics. A proteolytic queue was produced through 
the production of the CFP tagged with LAA which was expressed under an IPTG inducible 
promoter (Plac/ara-1), and YFP tagged with LAA which was expressed under dox inducible 
promoter (PLteto-1) (Fig. 3.5). Previously, this strain was used to study proteolytic 
queueing47. Our result indicates that when CFP-LAA and YFP-LAA were overexpressed 
using both IPTG and Dox inducers during three hours of ampicillin treatment, the queue 
was formed and leads to ~155-fold increase in the survival cells (Fig. 3.6). Furthermore, 
when CFP-LAA and YFP-LAA induced for 24 hours before ampicillin treatment, there 
was ~273-fold increase in the survival cells because of the queue formation (Fig. 3.7). 
However, when we induced either CFP and YFP alone for three hours during ampicillin 
treatment or 24 hours before ampicillin treatment, we found the survival cells population 
were increased 56.8-fold and 187-fold, respectively (Fig. 3.8,9).  
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Fig. 3.5. A. The p24kmNB82 plasmid produces CFP-LAA under the control of the Plac/ara-
1 promoter, while the p31CmNB95 generates YFP-LAA under the control of the PLteto-1 
promoter. B. The p24kmNB83 produces CFP-untagged under the control of the Plac/ara-1 
promoter, while p31CmNB02 produces YFP-untagged under control of the PLteto-1 
promoter. 
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Fig. 3.6  Induction of CFP-LAA and YFP-LAA for three hours during antibiotic treatment. 
Tolerant population increased by 7.4-fold and by 56.5-fold when Dox and IPTG were 
added separately. But when both inducers were added, the survival cells increased by ~155-
fold. Error bars represent standard deviation. Symbols (- -) mean without adding inducer, 
(+ -) adding IPTG inducer, (- +) adding dox inducer, (+ +) adding IPTG and dox inducer. 
n ≥ 3. 
 
 
Fig. 3.7 Induction of CFP-LAA and YFP-LAA for 24 hours before antibiotic treatment. 
Cultures induced with only Dox, only IPTG, or both. Error bars represent standard 
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deviation. Symbols (- -) mean without adding inducer, (+ -) adding IPTG inducer, (- +) 
adding dox inducer, (+ +) adding IPTG and dox inducer. n ≥ 3. 
 
 
Fig. 3.8 Induction of CFP and YFP alone during ampicillin treatment. Error bars represent 
SEM. Symbols (- -) mean without adding inducer, (+ -) adding IPTG inducer, (- +) adding 
dox inducer, (+ +) adding IPTG and dox inducer. n ≥ 3. 
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Fig. 3.9 Induction of CFP and YFP alone for 24 hours before ampicillin treatment. Error 
bars represent standard deviation. Symbols (- -) mean without adding inducer, (+ -) adding 
IPTG inducer, (- +) adding dox inducer, (+ +) adding IPTG and dox inducer. n ≥ 3. 
 
3.4. Design new plasmids for high-level production of tagged proteins without the 
PLteto-1 promoter 
Recently results from Prajakta Jadhav suggest that the PLteto-1 is active in the stationary 
phase. In other words, Dox does is not functioning as expected in stationary phase unless 
high concentrations are used. High concentrations of Dox (which is an antibiotic) 
negatively affects bacteria growth rates (unpublished results from Prajakta Jadhav). To 
work around this problem, I designed new synthetic circuits that have two copies of the 
fluorescent protein (CFP) genes with different tags under two different Plac/ara-1 promoter. 
Firstly, two primer sets were designed for cloning and screening (Table 3.2) (Fig. 3.10. A). 
Following the cloning steps (Fig. 3.11), the cloning failed. New plasmid primers were 
designed (Table 3.2) (Fig. 3.10. B) and future researchers will be tasks to finish this project. 
 
Table 3.2 Primers. Caps are highlighted in blue. Restriction enzyme sites (AvrII and MluI 
for first primers designed) and (AvrII and PciI for second primers designed) are in bold. 
The template annealing sequence is underlined. Annealing Temperature: AT. AA0F refers 
to the forward primer and AA0R refers to the reverse primer with respect to the 
transcription direction of the cfp gene. Future experiments will involve using these newly 
designed plasmids to test tolerance and persistence levels at the three major proteases in E. 
coli. 
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Primer Primers sequence 5’ to 3’ AT (oC) Function  
AA01F TCCCCTAGGCTGTGTGGAATTGTGAGCGGA 65 Cloning 
AA01R AGCACGCGTACCATGGGAT 65 Cloning  
AA02F GGATCCCATGGTACGCGTAC 59.7 Amplify 
AA02R GTAAGCGGCAGGGTCGGAAC 59.7 Amplify 
AA03F AAAACATGTCTGTGTGGAATTGTGAGCG 65 Cloning 
AA03R TCCCCTAGGGTTCACCGACAAACAACAG 58.3 Cloning 
AA04F TCCTGAGTAGGACAAATC 49.7 Amplify 
AA04R TTGGACTCAAGACGATAG 49.7 Amplify 
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Fig.3.10.A. Newly designed plasmids that include two copies of cfp-untagged 
(p24kmAA83), two copies of cfp-LAA tag (p24kmAA82), two copies of cfp-MarAn20 
(p24kmAA78), and two copies of cfp-RepA70 tag (p24kmAA07). AA01F refers to the 
forward, AA01R refers to the reverse primer used for colony PCR. AA02F refers to the 
forward, and AA02R refers to reverse primers used for screening. B. Redesign of the four 
plasmids using new primers set AA03F as a forward and AA03R as a reverse primer used 
for colony PCR. AA04 F as a forward screening primer, and AA04R as a reverse screening 
primer. 
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            Fig. 3.11 Cloning steps.  
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3.5. Discussion  
Mid-level expression of CFP-MarAn20 and CFP-RepA70 tags, which are degraded by 
Lon and ClpAP proteases, respectively, did increase tolerance population, but only slightly. 
This result was not surprising, since we knew from previous study that a queue was formed 
at these two proteases only when the tagged proteins were highly expressed, while 
queueing at ClpXP with LAA-tagged proteins occurs with mid-level expression47. Even 
though we used plasmids that have been used to study highly proteolytic queueing47; we 
faced a problem with the PLteto-1, which appeared to be active in stationary phase without 
induction. 
I started this project, and I was unable to complete it during my Master's program. 
However, I have laid the groundwork for future researchers. 
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Chapter 4 
 
Transcriptional analysis of stress response mechanisms at different growth phases 
in 
E. coli. 
 
 
The purpose of this project was to analyze the amount of toxin and antitoxin during 
bacteria different growth phases. I set out to test the hypothesis that the ratio of 
toxin:antitoxin (T:A) (as previously mentioned in Chapters 1 and 2) would be depended on 
growth phase. If so, we predict the T:A ratio would change so that in the toxin relative to 
antitoxin would be higher in stationary phase compared to log phase due to increased 
degradation of antitoxin in stationary phase. We know that TA systems are related to 
bacteria persistence, and persistence increases during stationary phase, so analysis of their 
transcription or translation would allow us to test this hypothesis.  
I used the publicly available RNA-sequencing (RNA-seq) datasets168 to quantify 
transcription rates during different growth phases. However, I was unable to continue this 
project due to the lack of valuable transcriptomics data, especially due to the lack of deep-
sequencing of RNA-Seq (TA systems are often produced at low levels). My labmate 
(Heather Deter) is currently working on RNA-Seq experiments to provide more data. 
 
 
 
 
 
 
79 
 
Chapter 5 
Conclusion and Future Study 
5.1. Future Study 
In this work, the expression of the LAA, MarAn20, and RepA70 tagged proteins were 
at a medium level, so we are planning to test higher level of LAA, MarAn20, RepA70 
tagged proteins expression. Because we know from previous a study that proteolytic 
queueing was only observed for MarAn20 (Lon target) and RepA70 (ClpAP target) tagged 
proteins when they were highly expressed47.  
In this work also, we did not indicate which protein(s) responsible for increase tolerance 
due to the overloading of ClpXP, but we do give many possible candidates that may be 
involved. Future work will be tested the effect of candidates (e.g. DksA and Fnr 
transcription factors or other regulatory proteins) that could be the reason for queueing-
tolerance. Our long-term goal is to make new drugs based on identify proteins that increase 
or decrease during queueing. To this future, experiments will likely involve analyzing 
population of cells at the single-cell level (e.g. microfluidic devices).  
5.2. Conclusion 
This work demonstrates that proteolytic queueing is a novel approach to study bacterial 
antibiotic persistence and tolerance without affecting the growth rate of bacteria. Our 
results clearly indicated that overloading the ClpXP protease with LAA-tagged proteins 
results in significant increase in tolerance, while untagged proteins do not. We observed 
the effect of proteolytic queueing in tolerant population in two different types of antibiotics 
(ampicillin and ciprofloxacin) and carbon sources (glycerol and glucose), and various times 
of induction of the queue. 
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RpoS, a global regulator of several genes, is degraded by ClpXP and has previously 
been demonstrated to participate in persistence. I set out to test if this protein is the reason 
behind increased tolerance during proteolytic queueing at ClpXP. So, we tested the effect 
of sigma factor RpoS, which is one of the major regulatory proteins in the stationary phase 
degraded by ClpXP protease169. Our result showed that RpoS is not responsible for the 
tolerance. Future research will require looking at other proteins (e.g. DksA) and their 
relationship to queueing-tolerance and ClpXP degradation. 
I also looked at the effect of proteolytic queueing at different proteases. The 
overexpression of RepA70 and MrnA20 linked to the CFP protein targeted two the other 
main proteases ClpAP and Lon, respectively, showed an increase in antibiotic survival, 
which needs further exploration. This worked demonstrated queueing-tolerance only in E. 
coli (one strain of E. coli), and future work may involve studying this phenomenon in many 
different bacteria.  
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